Medivation price target raised to $95 from $80 at Credit Suisse Credit Suisse raised Medvation's price target ahead of PREVAIL trial data on January 30. The firm has increased confidence in the data and raised 2015 and beyond estimates. Shares are Outperform rated.
News For MDVN From The Last 14 Days
Check below for free stories on MDVN the last two weeks.